Abstract
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Current Cardiology Reviews
Title:Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volume: 7 Issue: 4
Author(s): Maria Volkova and Raymond Russell
Affiliation:
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Abstract: Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Export Options
About this article
Cite this article as:
Volkova Maria and Russell Raymond, Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment, Current Cardiology Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157340311799960645
DOI https://dx.doi.org/10.2174/157340311799960645 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Current Drug Delivery How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design